Exabis Library
Welcome to the e-CCO Library!
P521: Correlation of histological assessment of mucosal healing with long-term clinical and patient-reported outcomes in patients with moderately to severely active ulcerative colitis treated with upadacitinib: results from the Phase 3 U-ACHIEVE maintenance trial
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P521: Effectiveness of ustekinumab as therapy for chronic antibiotic refractory pouchitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P521: Evaluation of adalimumab effectiveness in paediatric patients with ulcerative colitis in clinical practice
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P521: Pre-operative enteral nutrition in adults with Crohn’s disease: effect on gut microbiota and disease outcomes
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P522 Prior pharmacotherapy patterns among patients with IBD in the USA initiating biologic therapy
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P522: A multicenter study to validate Magnetic Resonance Enterography against histological assessments of stenotic disease in patients with Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P522: Effectiveness of tofacitinib in a real-world Israeli cohort of patients with moderate-severe ulcerative colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P522: Expression of markers of early atherosclerosis in inflammatory bowel disease: a prospective cohort of a single referral centre
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P522: Kono-S anastomosis reduces endoscopic and surgical post-operative recurrence in Crohn's disease. The SuPREMe-CD Trial Update.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P522: Soluble sMadCAM1 and retinoic acid are potential tools for therapeutic drug monitoring in inflammatory bowel disease s under vedolizumab: A proof of concept
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P522: Upadacitinib Promotes Histologic and Endoscopic Mucosal Healing: Results from the Upadacitinib Ulcerative Colitis Phase 3 Program
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P523 Improvement of quality of life and continence in patients with distal ulcerative colitis treated by mesalazine: QUARTZ study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P523: Association between pharmacokinetics of adalimumab and disease outcome in Japanese patients with biologics naïve Crohn's disease: a subanalysis of DIAMOND trial
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P523: effectiveness of biological treatments for inflammatory bowel disease in the elderly patients
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P523: Endoscopic balloon dilatation is safe and has a high success rate in patients with stricturing Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P523: New guidance on therapeutic drug monitoring; potential clinical and cost implication
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P523: Quality, safety and equity of care outcomes for inflammatory bowel disease patients at four tertiary referral centres in Australia using a cloud based management system Crohn's Colitis Care (CCCare): A real world observational study.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P523: Survey to identify patient characteristics, treatment preferences and impact of inflammatory bowel disease (IBD) on quality of life across 7 countries in Europe
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P524 Administration and monitoring of biologic therapy in patients with inflammatory bowel disease: A national Danish survey
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P524: Active smoking and personal concerns about treatment can impair adherence to adalimumab in inflammatory bowel diseases: A prospective evaluation
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM